Transforming respiratory outcomes with AI and data analytics
aflo™ uses AI, and sensors to automate inhaler technique. aflo™ helps to get medication deep into the lungs, improving asthma, COPD and cystic fibrosis outcomes
Managing your airways condition
Our goal for aflo™ is to improve the management of respiratory conditions for patients and clinicians, saving lives, reducing costs and improving outcomes.
The scale of the problem
A recent meta-analysis concluded that 86% of inhaler users made at least 1 inhalation error and that 50% experience a critical inhalation error leading to poor symptom control, increased risk of hospitalisation and a higher risk of mortality.
By 2025 asthma prevalence will rise to 400 million and by 2032 COPD will be the leading cause of death.
In the UK and Ireland alone there are over 5.9 million people diagnosed with asthma and over 1.4 million with COPD and using inhaled medications.
- Inhaler technique error is associated with poorer outcomes in asthma and COPD
- Improving inhaler technique results in improved Quality of Life (QoL) scores
- Inhaler technique error increases healthcare costs
‘Definitely helped my inhaler technique’
Reduce your symptoms with aflo
aflo™ will teach you how to inhale your medicines correctly and aggregate your daily inhalation scores with air quality and viral data to help you to manage the symptoms that reduce your quality of life.
aflo™ is a smart tool for airways conditions monitoring. Start using aflo™ and take control of your asthma, COPD and cystic fibrosis today.